Chime Biologics Congratulates Polpharma Biologics on Global Licensing Agreement with Teva for Ocrelizumab Biosimilar Candidate
Article Date
July 14, 2026
This article is featured on another website.
Go to article
June 23, 2026
HiRO at BIO Asia–Taiwan: Advancing Global Clinical Development Together
Collaborating Across APAC at BIO Asia–Taiwan to Advance High‑Quality Cross‑Border Clinical Research Harvest Integrated Research…
June 23, 2026
HiRO at BIO Asia–Taiwan: Advancing Global Clinical Development Together
Collaborating Across APAC at BIO Asia–Taiwan to Advance High‑Quality Cross‑Border Clinical Research Harvest Integrated Research…
July 10, 2026
Sarcoma Clinical Trials – Cell Therapy’s Solid-Tumor Breakthrough, and What It Means for a Rare Cancer
A Turning Point for Cell Therapy in Solid Tumors, and for Sarcoma For most of…
July 10, 2026
Sarcoma Clinical Trials – Cell Therapy’s Solid-Tumor Breakthrough, and What It Means for a Rare Cancer
A Turning Point for Cell Therapy in Solid Tumors, and for Sarcoma For most of…